The role of telomerase reverse transcriptase (TERT) gene promoter mutations in the
aggressiveness of papillary thyroid cancer (PTC) remains to be further investigated. Here we …

Background: The primary goals of this interdisciplinary consensus statement are to define
the eligibility criteria for management of recurrent and persistent cervical nodal disease in …

Purpose: The extent to which routine genomic sequencing can identify relevant secondary
genomic alterations among BRAFV600E-mutant papillary thyroid carcinoma (PTC) is …

There is no effective treatment for patients with poorly differentiated papillary thyroid cancer
or anaplastic thyroid cancer (ATC). Anlotinib, a multi-kinase inhibitor, has already shown …

Context Multifocality is often treated as a risk factor for papillary thyroid cancer (PTC),
prompting aggressive treatments, but its prognostic value remains unestablished. Objective …

Background: There remain a small number of patients with papillary thyroid cancer (PTC)
who suffer recurrence, metastases, or death. While mutation of the BRAF gene …

Background: Given the increasing incidence of papillary thyroid carcinoma despite stable
disease-specific mortality rates, the potential for the disease to reoccur is a key outcome to …

Objective To investigate the mutant status of BRAF gene and analyze its relationship to
epidemiological risk factors and clinical outcomes among patients with papillary thyroid …

Thyroid papillary carcinoma is the most common endocrine neoplasm and generally carries
a favorable prognosis. However, a small subset of papillary carcinomas transforms into …

Background: Molecular testing for oncogenic gene mutations and chromosomal
rearrangements plays a growing role in the optimal management of thyroid nodules, yet …